Navigation Links
Cambrex to Announce First Quarter 2008 Financial Results on May 1, 2008
Date:4/24/2008

EAST RUTHERFORD, N.J., April 24 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced that it will release first quarter 2008 financial results on Thursday, May 1, 2008 after market close.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )

The Company will host a conference call to discuss the first quarter 2008 financial results.

First Quarter 2008 Earnings Conference Call

When: Thursday, May 1, 2008 at 5:00 p.m. Eastern Time

Dial-in: 1-888-634-4003 for U.S.

1-706-634-6653 for International

Pass code: 44524695

Dial-in Replay: 1-800-642-1687 for U.S.

1-706-645-9291 for International

Pass code: 44524695

Available through Thursday, May 8, 2008

Webcast: http://www.cambrex.com

Available for 30 days following the conference call

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients ("APIs"), advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit http://www.cambrex.com.


'/>"/>
SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
2. Cambrex Signs Agreement To Acquire ProSyntest AS
3. Cambrex Reports Fourth Quarter and Full-Year 2007 Results
4. Cambrex Customer Announced Recall
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) ... part of the second annual Apples for Education: Buy an Apple, Help a ... providing healthy food for students to take home to their families; solar technology to ...
(Date:12/5/2016)... ... ... “Life Will Never Be The Same” is a fictional tale about growing up with ... is the creation of published author, Kim T. Briggs, a self-described “big kid” who ... religion and philosophy from Judson University in Elgin, Illinois. Having written numerous Christian drama ...
(Date:12/5/2016)... ... 2016 , ... The new knee compression sleeves come as a pair which ... sleeves for lifting and any sport that requires knee compression or protection from ... provide a higher quality knee sleeve performance. Firstly it is made out of premium ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... that they have teamed up with The American College of Surgeons (ACS) to ... Committee on Trauma, the “Bleeding Control Basic” course is a pilot program that ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... transitions and many more tools allowing FCPX editors to create professional looking video ... Studios. , Perfect Harmony contains a beautifully designed 3D environment for placing ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the ... SelG1), an anti-P-selectin antibody, reduced the median annual rate ... to placebo (1.63 vs 2.98, p=0.010) in patients with ... that the data are being featured in the official ... of Hematology (ASH) Annual Meeting and presented during the ...
(Date:12/2/2016)... SPRING, Md. , Dec. 2, 2016 ... new indication for Jardiance (empagliflozin) to reduce the risk ... diabetes mellitus and cardiovascular disease. "Cardiovascular ... with type 2 diabetes mellitus," said Jean-Marc Guettier ... and Endocrinology Products in FDA,s Center for Drug Evaluation ...
Breaking Medicine Technology: